Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other financing activities (2018 - 2023)

Spyre Therapeutics' Other financing activities history spans 7 years, with the latest figure at $1.8 million for Q2 2023.

  • For Q2 2023, Other financing activities fell 12.0% year-over-year to $1.8 million; the TTM value through Jun 2023 reached $6.5 million, down 22.14%, while the annual FY2024 figure was $1000.0, 106.25% up from the prior year.
  • Other financing activities reached $1.8 million in Q2 2023 per SYRE's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.1 million in Q3 2021 to a low of $1.1 million in Q1 2019.
  • Average Other financing activities over 5 years is $1.7 million, with a median of $1.7 million recorded in 2020.
  • Peak YoY movement for Other financing activities: soared 36.15% in 2020, then plummeted 31.85% in 2022.
  • A 5-year view of Other financing activities shows it stood at $1.2 million in 2019, then surged by 36.15% to $1.6 million in 2020, then rose by 29.9% to $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then increased by 24.39% to $1.8 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Other financing activities are $1.8 million (Q2 2023), $1.7 million (Q1 2023), and $1.4 million (Q4 2022).